A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
Active, not recruiting · NCT05733546 · Registry updated 2025-08-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder | depressive disorder, major depressive disorder, mood disorder, psychiatric disorder | Active, not recruiting | Phase 2 | 2025-08-19 | NCT05733546 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| COMPASS Pathways | 4 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aims Trial | Plano | United States | 1 |
| Clinical NeuroScience Solutions Inc | Jacksonville | United States | 3 |
| Elixia MA, LLC | Springfield | United States | 3 |
| Kadima Neuropsychiatry Institute | La Jolla | United States | 11 |
| Sunstone Therapies | Rockville | United States | 4 |